CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P92
Near historical high
vs 2Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 35.66% |
| Q3 2025 | 14.88% |
| Q2 2025 | -29.39% |
| Q1 2025 | 27.57% |
| Q4 2024 | -30.78% |
| Q3 2024 | -15.11% |
| Q2 2024 | 14.15% |
| Q1 2024 | 13.75% |
| Q4 2023 | 85.87% |
| Q3 2023 | -48.10% |
| Q2 2023 | -2.51% |
| Q1 2023 | 5.38% |
| Q4 2022 | -34.31% |
| Q3 2022 | -4.42% |
| Q2 2022 | 1.96% |
| Q1 2022 | -14.97% |
| Q4 2021 | 23.32% |
| Q3 2021 | 11.66% |
| Q2 2021 | 16.67% |
| Q1 2021 | 1.65% |
| Q4 2020 | -8.49% |
| Q3 2020 | -0.07% |
| Q2 2020 | -43.79% |
| Q1 2020 | 17.49% |
| Q4 2019 | 30.30% |
| Q3 2019 | -9.30% |
| Q2 2019 | -15.23% |
| Q1 2019 | 28.51% |
| Q4 2018 | 2.75% |
| Q3 2018 | 7.81% |
| Q2 2018 | 13.78% |
| Q1 2018 | 8.47% |
| Q4 2017 | -28.41% |
| Q3 2017 | 3.01% |
| Q2 2017 | 92.62% |
| Q1 2017 | -5.03% |
| Q4 2016 | 15.08% |
| Q3 2016 | 4.97% |
| Q2 2016 | -4.94% |
| Q1 2016 | 40.64% |